Requires Prescription (YES/NO)
Yes
How it works
Tranexamic acid competitively inhibits activation of plasminogen(via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Usage And Safety
Dosage
Inj: Inhibition of fibrinolysis, hereditary angioedema: INJ: By IV injection over at least 10 minutes, 1-18yr, 10mg/kg (max 1 gm) 2-3 times daily. By continuous IV infusion, 1-18 yr, 45mg/kg over 24 hr. Prevention of excessive bleeding after dental procedures ( e.g in haemophilia ): inj: By IV injection pre-operatively, 6-18yr, 15-25mg/kg ( max 1.5gm), Local fibrinolysis: 15-25mg/kg body weight two-three times daily. OR As directed by your physician.
Side Effects
Hypotension has occurred, particularly after rapid intravenous dosage. Thrombotic complications have been reported in patients receiving tranexamic acid, but these are usually a consequence of its inappropriate use. There have been a few instances of transient disturbance of color vision associated with use of tranexamic acid. Hypersensitivity skin reactions have also been reported.
Drug Interactions
Estrogens, Thrombolytic drugs.
Indication
Tranexamic acid is indicated for the treatment of: – Hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenolysis .
When not to Use
Tranexamic acid is contraindicated in patients with:- Known hypersensitivity to tranexamic acid or to any of the excipient of the product.- Acute thromboembolic disease such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis.- Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding.
Warnings
Warning 1
Intravenous Injection of tranexamic acid should be given very slowly.
Warning 2
In case of haematuria from the upper urinary tract, there is a risk for urethral obstruction.
Warning 3
Attention should be paid to possible visual disturbances including visual impairment, vision blurred, impaired color vision and if necessary the treatment should be discontinued. With continuous long-term use of tranexamic acid, regular ophthalmologic examinations .
